374 results on '"Siddik, Zahid H."'
Search Results
2. Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents
3. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy
4. Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights
5. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis
6. Optimization of nanostructured lipid carriers: understanding the types, designs, and parameters in the process of formulations
7. Targeting p21-Dependent Pathways for Cell Death in Cancer Therapy
8. Drug Resistance and the Tumor Suppressor p53: The Paradox of Wild-Type Genotype in Chemorefractory Cancers
9. ATP11B mediates platinum resistance in ovarian cancer
10. Supplementary Data from Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity
11. Supplementary Data from Therapeutic Targeting of ATP7B in Ovarian Carcinoma
12. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
13. Cisplatin Resistance : Molecular Basis of a Multifaceted Impediment
14. Alkylating Agents and Platinum Antitumor Compounds
15. Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]
16. Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma
17. Biochemical and Molecular Mechanisms of Cisplatin Resistance
18. Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53
19. The impact of S- and G2-checkpoint response on the fidelity of G1-arrest by cisplatin and its comparison to a non-cross-resistant platinum(IV) analog
20. Pharmacological Studies with New Liposome-Entrapped Cisplatin Derivatives
21. Development and validation of a reversed-phase HPLC method for quantification of 1’-acetoxychavicol acetate content in a nanostructured lipid carrier formulation
22. Abstract P053: VAL-083 (dianhydrogalactitol) synergizes with PARP inhibitors in BRCA-proficient and BRCA-deficient ovarian cancer models
23. Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape
24. ATP11B mediates platinum resistance in ovarian cancer
25. Protein kinase inhibitors emodin and dichloro-ribofuranosylbenzimidazole modulate the cellular accumulation and cytotoxicity of cisplatin in a schedule-dependent manner
26. Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma
27. Abstract 1073: Preclinical tissue biodistribution and plasma pharmacokinetic studies with oxaliTEX, a novel platinum(IV)-based oxaliplatin prodrug
28. Apoptosis in Cancer
29. Contributors
30. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities
31. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents
32. Cisplatin: mode of cytotoxic action and molecular basis of resistance
33. Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity
34. The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells
35. Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents
36. Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [Pt IV( trans-1 R,2 R-diaminocyclohexane) trans-(acetate) 2(9-ethylguanine)Cl]NO 3 · H 2O
37. Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro
38. Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin
39. Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes
40. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells
41. Kinetics of tissue disposition ofcis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSallC tumors
42. Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration
43. Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes
44. Increased Sensitivity of a Metastatic Model of Prostate Cancer to a Novel Tetravalent Platinum Analog
45. Pharmacokinetics of liposome-entrappedcis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat
46. Extracorporeal hemofiltration: a model for decreasing systemic drug exposure with intra-arterial chemotherapy
47. Assessment of pulmonary and hematologic toxicities of liblomycin, a novel bleomycin analog
48. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tum3or cells
49. Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells
50. Preparation, characterization, and antitumor activity of new cisplatin analogues with 1-methyl-4-(methylamino)piperidine: Crystal structure of [Pt II(1-methyl-4-(methylamino) piperidine)(oxalate)]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.